Sign in Subscribe

systematic-review

A collection of 29 issues

Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients

Skip to content The CRC Digest ◇ RESEARCH Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients A systematic review and meta-analysis examined the diagnostic yield of germline multigene panel testing using next-generation sequencing in unselected patients with colorectal cancer, helping clarify how often inherited genetic factors contribute to diagnosis. (Lancet

Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways

Skip to content The CRC Digest Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways Review identifies obesity, metabolic conditions, poor diet, and sedentary behavior as key EOCRC risk factors, with growing evidence for early-life and gut microbial exposures. (Nature Reviews Cancer) This content is informational

Scoping Review Identifies Barriers to Diagnostic Colonoscopy After Positive Stool-Based Screening

Skip to content The CRC Digest ▪ SCREENING Scoping Review Identifies Barriers to Diagnostic Colonoscopy After Positive Stool-Based Screening Systematic review synthesizes barriers and facilitators to completing diagnostic colonoscopy after a positive non-invasive stool-based screening test (FIT, gFOBT, or multitarget stool DNA), emphasizing that timely follow-up colonoscopy is essential for reducing

Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea

Skip to content The CRC Digest ♥ LIVING WITH CRC Comprehensive Review Examines Mechanisms and Management of Irinotecan-Induced Delayed Diarrhea A systematic review details how irinotecan's active metabolite SN38 affects the intestinal microenvironment—including flora disruption, immune dysregulation, and barrier impairment—and explores current therapeutic approaches to manage this

Adjuvant chemotherapy benefits occur early, not in late recurrences

Skip to content The CRC Digest ◆ TRIAL DATA Adjuvant chemotherapy benefits occur early, not in late recurrences A systematic review of phase III randomized controlled trials for gastrointestinal malignancies including colorectal cancer found that recurrence-free survival improvements were driven by early divergences during active chemotherapy, while late recurrences were not

Multitarget stool DNA test shows promise over standard FIT screening

Skip to content The CRC Digest ▪ SCREENING Multitarget stool DNA test shows promise over standard FIT screening A systematic review found that multitarget stool DNA (mt-sDNA) testing emerged as a promising alternative to faecal immunochemical test (FIT) for detecting colorectal neoplasms, particularly given FIT's low sensitivity for advanced

Systematic review identifies factors affecting cancer screening participation among survivors

Skip to content The CRC Digest Systematic review identifies factors affecting cancer screening participation among survivors A meta-analysis examined predictors of participation in breast and colorectal cancer screening among cancer survivors, who are at increased risk of subsequent primary cancers but show suboptimal screening uptake. (Journal of Cancer Survivorship) This

Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease

Skip to content The CRC Digest ▪ RESEARCH Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease A translational science review in JAMA reports that circulating tumor DNA (ctDNA) sequencing can identify gene variants to inform treatment selection in colorectal cancer, and that detecting ctDNA after curative intent therapy correlates

ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer

Skip to content The CRC Digest ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer DYNAMIC-III found that escalation in ctDNA-positive stage III patients did not improve outcomes. (EClinicalMedicine) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection

Skip to content The CRC Digest ◇ RESEARCH ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection A review of circulating tumor DNA in GI cancers found that while postoperative ctDNA positivity identifies high-risk patients, recent trials show mixed results: DYNAMIC-III showed escalation in ctDNA-positive stage III disease